InspireMD (NYSE:NSPR) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of InspireMD (NYSE:NSPR) in a report published on Sunday morning. The firm issued a sell rating on the stock.

InspireMD Price Performance

InspireMD stock opened at $2.59 on Friday. The stock’s 50 day moving average is $2.80 and its 200 day moving average is $2.74. InspireMD has a one year low of $1.87 and a one year high of $3.80. The firm has a market cap of $79.34 million, a P/E ratio of -3.45 and a beta of 0.74.

Institutional Investors Weigh In On InspireMD

Large investors have recently modified their holdings of the company. Parkman Healthcare Partners LLC grew its holdings in InspireMD by 721.2% during the 4th quarter. Parkman Healthcare Partners LLC now owns 854,716 shares of the company’s stock worth $2,248,000 after acquiring an additional 750,635 shares during the period. Affiance Financial LLC increased its holdings in InspireMD by 2.9% in the fourth quarter. Affiance Financial LLC now owns 189,122 shares of the company’s stock worth $497,000 after purchasing an additional 5,376 shares in the last quarter. Essex Investment Management Co. LLC acquired a new position in InspireMD in the fourth quarter valued at approximately $191,000. Northern Trust Corp boosted its holdings in shares of InspireMD by 103.7% during the 4th quarter. Northern Trust Corp now owns 48,022 shares of the company’s stock worth $126,000 after buying an additional 24,452 shares in the last quarter. Finally, Schonfeld Strategic Advisors LLC increased its stake in shares of InspireMD by 153.2% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 30,133 shares of the company’s stock valued at $79,000 after acquiring an additional 18,233 shares in the last quarter. 44.78% of the stock is currently owned by institutional investors and hedge funds.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.